GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DHG Pharmaceutical JSC (STC:DHG) » Definitions » Piotroski F-Score

DHG Pharmaceutical JSC (STC:DHG) Piotroski F-Score : 4 (As of May. 12, 2024)


View and export this data going back to 2006. Start your Free Trial

What is DHG Pharmaceutical JSC Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

DHG Pharmaceutical JSC has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for DHG Pharmaceutical JSC's Piotroski F-Score or its related term are showing as below:

STC:DHG' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 5   Max: 8
Current: 4

During the past 13 years, the highest Piotroski F-Score of DHG Pharmaceutical JSC was 8. The lowest was 4. And the median was 5.


DHG Pharmaceutical JSC Piotroski F-Score Historical Data

The historical data trend for DHG Pharmaceutical JSC's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DHG Pharmaceutical JSC Piotroski F-Score Chart

DHG Pharmaceutical JSC Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 7.00 5.00 8.00 4.00

DHG Pharmaceutical JSC Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 8.00 7.00 5.00 4.00

Competitive Comparison of DHG Pharmaceutical JSC's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, DHG Pharmaceutical JSC's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DHG Pharmaceutical JSC's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DHG Pharmaceutical JSC's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where DHG Pharmaceutical JSC's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was 360963.161 + 263335.72 + 166075.552 + 260288.226 = ₫1,050,663 Mil.
Cash Flow from Operations was -20087.772 + 94287.003 + 5451.72 + 160520.264 = ₫240,171 Mil.
Revenue was 1228558.027 + 1152649.915 + 1099461.735 + 1534725.363 = ₫5,015,395 Mil.
Gross Profit was 614145.373 + 561652.368 + 514651.633 + 653095.669 = ₫2,343,545 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(5168186.503 + 5502985.756 + 5724777.597 + 5989488.997 + 6110474.221) / 5 = ₫5699182.6148 Mil.
Total Assets at the begining of this year (Dec22) was ₫5,168,187 Mil.
Long-Term Debt & Capital Lease Obligation was ₫0 Mil.
Total Current Assets was ₫4,642,193 Mil.
Total Current Liabilities was ₫1,189,242 Mil.
Net Income was 255300.417 + 234569.89 + 262386.791 + 236197.548 = ₫988,455 Mil.

Revenue was 1064775.387 + 1119267.005 + 1161685.135 + 1330288.482 = ₫4,676,016 Mil.
Gross Profit was 504633.413 + 553714.518 + 578262.742 + 620884.27 = ₫2,257,495 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(4614517.068 + 4750344.782 + 5121518.147 + 4757356.414 + 5168186.503) / 5 = ₫4882384.5828 Mil.
Total Assets at the begining of last year (Dec21) was ₫4,614,517 Mil.
Long-Term Debt & Capital Lease Obligation was ₫0 Mil.
Total Current Assets was ₫4,218,772 Mil.
Total Current Liabilities was ₫811,537 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

DHG Pharmaceutical JSC's current Net Income (TTM) was 1,050,663. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

DHG Pharmaceutical JSC's current Cash Flow from Operations (TTM) was 240,171. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=1050662.659/5168186.503
=0.20329426

ROA (Last Year)=Net Income/Total Assets (Dec21)
=988454.646/4614517.068
=0.21420544

DHG Pharmaceutical JSC's return on assets of this year was 0.20329426. DHG Pharmaceutical JSC's return on assets of last year was 0.21420544. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

DHG Pharmaceutical JSC's current Net Income (TTM) was 1,050,663. DHG Pharmaceutical JSC's current Cash Flow from Operations (TTM) was 240,171. ==> 240,171 <= 1,050,663 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=0/5699182.6148
=0

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=0/4882384.5828
=0

DHG Pharmaceutical JSC's gearing of this year was 0. DHG Pharmaceutical JSC's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=4642192.911/1189241.981
=3.90348893

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=4218772.328/811536.702
=5.1984985

DHG Pharmaceutical JSC's current ratio of this year was 3.90348893. DHG Pharmaceutical JSC's current ratio of last year was 5.1984985. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

DHG Pharmaceutical JSC's number of shares in issue this year was 130.746. DHG Pharmaceutical JSC's number of shares in issue last year was 130.746. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2343545.043/5015395.04
=0.46727028

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2257494.943/4676016.009
=0.4827817

DHG Pharmaceutical JSC's gross margin of this year was 0.46727028. DHG Pharmaceutical JSC's gross margin of last year was 0.4827817. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=5015395.04/5168186.503
=0.97043616

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=4676016.009/4614517.068
=1.01332728

DHG Pharmaceutical JSC's asset turnover of this year was 0.97043616. DHG Pharmaceutical JSC's asset turnover of last year was 1.01332728. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+1+0+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

DHG Pharmaceutical JSC has an F-score of 4 indicating the company's financial situation is typical for a stable company.

DHG Pharmaceutical JSC  (STC:DHG) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


DHG Pharmaceutical JSC Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of DHG Pharmaceutical JSC's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


DHG Pharmaceutical JSC (STC:DHG) Business Description

Traded in Other Exchanges
N/A
Address
288 Bis Nguyen Van Cu, An Hoa Ward, Ninh Kieu District, Can Tho, VNM
DHG Pharmaceutical JSC produces and trades in pharmaceutical products. It provides various pharmaceutical products in the areas of antibiotic, antifungal, and antiparasitic; analgesic and antipyretic; ear-nose-throat, cough, and asthma; ophthalmic and nervous system; muscular and osteoarticular; digestive; hepatic; cardiovascular and diabetic; vitamins and minerals; and dermal and beauty care.

DHG Pharmaceutical JSC (STC:DHG) Headlines